Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Living Cell Technologies ( (AU:1AI) ) has provided an update.
Algorae Pharmaceuticals has released its half-year report for the six months ended 31 December 2025, providing the market with an update on its activities and financial performance over the period. The announcement, approved by the board, underscores the company’s dual-track strategy of advancing AI-driven drug discovery alongside expanding its commercial medicines business in Australia and New Zealand.
By highlighting both its proprietary AlgoraeOS platform and the AlgoraeRx commercialisation arm, the update reinforces Algorae’s positioning at the intersection of AI technology and traditional pharmaceuticals. This integrated model is intended to support the translation of AI-predicted therapies into practice while broadening patient access to high-quality medicines through research collaborations and established distribution channels.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian pharmaceutical company focused on AI-enabled drug discovery and pharmaceutical commercialisation in Australia and New Zealand. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations and guide preclinical experimental design, while its AlgoraeRx unit sources, licenses and supplies generic and specialty medicines via manufacturing partners and established distribution channels.
YTD Price Performance: 21.43%
Average Trading Volume: 2,043,058
Technical Sentiment Signal: Buy
Current Market Cap: A$30.61M
Learn more about 1AI stock on TipRanks’ Stock Analysis page.